| Ms Christine Mae Aurit, OTR/L | |
|
15750 E 1st Ave, Aurora, CO 80011 | |
| (303) 340-0510 | |
| Not Available |
| Full Name | Ms Christine Mae Aurit |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 15750 E 1st Ave, Aurora, Colorado |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275016982 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | OT.0004235 (Colorado) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Christine Mae Aurit, OTR/L 15750 E 1st Ave, Aurora, CO 80011 Ph: (303) 340-0510 | Ms Christine Mae Aurit, OTR/L 15750 E 1st Ave, Aurora, CO 80011 Ph: (303) 340-0510 |
News Archive
BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced today the launch of a new registry to collect long term data of CERAMENT™|G, the first injectable antibiotic eluting, osteoconductive, ceramic bone substitute indicated to promote and protect bone healing being jeopardized by infection.
Ipsen, a global biopharmaceutical group, today announced that its partner Roche has disclosed results of the phase III T-emerge 3 study in patients with diabetes with taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence. Taspoglutide originating from Ipsen's research is developed by Roche.
In a paper published in the journal Pain, Saint Louis University researcher Daniela Salvemini, Ph.D., reports discovering a key molecular pathway that drives cancer-related bone pain while providing a potential solution with a drug that already is on the market.
While making smart glue, a team of engineers discovered a handy byproduct: hydrogen peroxide. In microgel form, it reduces bacteria and virus ability to infect by at least 99 percent.
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced four-year follow-up results from a Phase 3 randomized, open-label, dose-optimization study of SPRYCEL® (dasatinib) in chronic-phase chronic myeloid leukemia (CML-CP) patients resistant or intolerant to Gleevec®* (imatinib mesylate). At four years, for all patients administered SPRYCEL 100 mg once daily, overall survival was 82% (95% CI: 76%-88%) and progression-free survival was 66% (95% CI: 57%-74%).
› Verified 2 days ago
Ms. Carol Yvonne Wall, O.T.R., C.E.A.S Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3451 S Chambers Rd, Aurora, CO 80014 Phone: 303-680-6121 Fax: 303-680-8627 | |
Hatti Owens, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 15751 E 1st Ave, Aurora, CO 80011 Phone: 303-340-0510 | |
Mrs. Sanja June Batz, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 13123 E 16th Ave, Aurora, CO 80045 Phone: 720-777-7447 | |
Lilly O'toole, OTD Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 7795 S Blackstone Pkwy, Aurora, CO 80016 Phone: 720-886-1400 | |
Susanna Muth, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 24300 E Progress Dr, Aurora, CO 80016 Phone: 720-886-4000 | |
Alexis Reinert, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 5954 S Quatar Ct, Aurora, CO 80015 Phone: 303-250-4291 Fax: 720-306-2352 | |
Alyssa Fasoli, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 15701 E 1st Ave Ste 109, Aurora, CO 80011 Phone: 303-367-3060 |